Those Reason 2 O O
who Reason 2 O O
were Reason 2 O O
previously Reason 2 O O
infected Reason 2 O O
with Reason 2 O O
COVID-19 Reason 2 O O
were Reason 2 O O
more Reason 2 O O
likely Reason 2 O O
to Reason 2 O O
experience Reason 2 O O
swollen Reason 2 O O
lymph Reason 2 O O
nodes Reason 2 O O
after Reason 2 O O
their Reason 2 O O
first Reason 2 O O
dose Reason 2 O O
of Reason 2 O O
Pfizer's Reason 2 O O
vaccine Reason 2 O O
compared Reason 2 O O
to Reason 2 O O
those Reason 2 O O
without Reason 2 O O
a Reason 2 O O
prior Reason 2 O O
documented Reason 2 O O
infection, Reason 2 O O
according Reason 2 O O
to Reason 2 O O
research Reason 2 O O
published Reason 2 O O
April Reason 2 O O
22 Reason 2 O O
in Reason 2 O O
the Reason 2 O O
preprint Reason 2 O O
server Reason 2 O O
[medRxiv](https://www.medrxiv.org/content/10.1101/2021.04.15.21252192v1). Reason 2 O O
Researchers O O O O
in O O O O
the O O O O
U.K. O O O O
conducted O O O O
an O O O O
observational O O O O
study O O O O
that O O O O
looked O O O O
at O O O O
adverse O O O O
events O O O O
after O O O O
COVID-19 O O O O
vaccination. O O O O
A O O O O
total O O O O
of O O O O
947 O O O O
healthcare O O O O
workers O O O O
across O O O O
three O O O O
hospitals O O O O
participated O O O O
in O O O O
the O O O O
study O O O O
by O O O O
self-reporting O O O O
symptoms O O O O
after O O O O
vaccination. O O O O
Of O O O O
those, O O O O
265 O O O O
participants O O O O
had O O O O
previously O O O O
tested O O O O
positive O O O O
for O O O O
the O O O O
virus. O O O O
Overall, Reason 2 O O
those Reason 2 O O
who Reason 2 O O
previously Reason 2 O O
contracted Reason 2 O O
COVID-19 Reason 2 O O
were Reason 2 O O
more Reason 2 O O
likely Reason 2 O O
to Reason 2 O O
report Reason 2 O O
at Reason 2 O O
least Reason 2 O O
one Reason 2 O O
moderate Reason 2 O O
to Reason 2 O O
severe Reason 2 O O
symptom Reason 2 O O
compared Reason 2 O O
to Reason 2 O O
those Reason 2 O O
without Reason 2 O O
a Reason 2 O O
prior Reason 2 O O
infection, Reason 2 O O
at Reason 2 O O
56 Reason 2 O O
percent Reason 2 O O
and Reason 2 O O
47 Reason 2 O O
percent, Reason 2 O O
respectively. Reason 2 O O
Specifically, Reason 2 O O
those Reason 2 O O
in Reason 2 O O
the Reason 2 O O
previous Reason 2 O O
COVID-19 Reason 2 O O
group Reason 2 O O
were Reason 2 O O
significantly Reason 2 O O
more Reason 2 O O
likely Reason 2 O O
to Reason 2 O O
experience Reason 2 O O
lymphadenopathy, Reason 2 O O
or Reason 2 O O
swollen Reason 2 O O
lymph Reason 2 O O
nodes, Reason 2 O O
as Reason 2 O O
well Reason 2 O O
as Reason 2 O O
fever, Reason 2 O O
fatigue, Reason 2 O O
myalgia Reason 2 O O
and Reason 2 O O
arthralgia. Reason 2 O O
About Reason 2 O O
4 Reason 2 O O
percent Reason 2 O O
of Reason 2 O O
participants Reason 2 O O
with Reason 2 O O
a Reason 2 O O
COVID-19 Reason 2 O O
history Reason 2 O O
experienced Reason 2 O O
lymphadenopathy, Reason 2 O O
compared Reason 2 O O
to Reason 2 O O
less Reason 2 O O
than Reason 2 O O
1 Reason 2 O O
percent Reason 2 O O
of Reason 2 O O
those Reason 2 O O
who Reason 2 O O
weren't Reason 2 O O
infected. Reason 2 O O
"This Reason 2 O O
study Reason 2 O O
of Reason 2 O O
healthcare Reason 2 O O
workers Reason 2 O O
demonstrated Reason 2 O O
that Reason 2 O O
prior Reason 2 O O
COVID-19 Reason 2 O O
infection, Reason 2 O O
but Reason 2 O O
not Reason 2 O O
long Reason 2 O O
COVID-19, Reason 2 O O
is Reason 2 O O
associated Reason 2 O O
with Reason 2 O O
an Reason 2 O O
increased Reason 2 O O
risk Reason 2 O O
of Reason 2 O O
[adverse Reason 2 O O
events] Reason 2 O O
including Reason 2 O O
lymphadenopathy Reason 2 O O
following Reason 2 O O
... Reason 2 O O
vaccination," Reason 2 O O
researchers Reason 2 O O
said. Reason 2 O O
